Quetiapine in Patients With Tourette's Disorder: An Open-Label, Flexible-Dose Study
J Clin Psychiatry 2007;68(7):1148-1150 [letter]
© Copyright 2014 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.
Sir: Tourette’s disorder (TD), or Gilles de la Tourette’s syndrome, is a neuropsychiatric disorder, usually starting in early childhood, characterized by multiple motor and vocal tics.
Although the etiology of TD remains largely unknown, it has been hypothesized that overactivity or hypersensitivity of the D2 receptors in the striatum plays a role.1 This hypothesis is consistent with the proved effectiveness of central D2-blocking agents like haloperidol and pimozide that decrease the intensity and frequency of tics in approximately 70% of the patients.